Navigation Links
Pharmaxis Investor Conference Call
Date:4/6/2009

SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- Pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL) will release its March 2009 Quarterly Report to Shareholders on the afternoon of Wednesday 8th April 2009. Dr Alan Robertson will host an investor teleconference the following morning to review the quarter and answer investor questions.

The teleconference will be on Thursday 9th April at 8.00am (Sydney), (Wednesday 8th April at 6.00pm U.S. East Coast, 3.00pm U.S. West Coast).

    Telephone access (toll free) details are below:
    -- Australia: 1800 131 617
    -- USA/Canada:  866 746 2596
    -- UK: 0800 376 8339
    -- NZ: 0800 446 958
    -- Switzerland: 0800 001 230
    -- Online (global access):
      http://services.choruscall.com/links/pharmaxis090409.html

A recording of the conference will be available on the Pharmaxis website home page approximately 3 hours after the call.

    CONTACT:

     Pharmaxis Investor Relations
     Tel:     +61-2-9454-7200
     Fax:     +61-2-9451 3622,
     Email:   Investor.Relations@Pharmaxis.com.au
     Website:http://www.pharmaxis.com.au

'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pharmaxis Appoints French Distributor for Aridol(TM)
2. Pharmaxis Builds Senior Management Team
3. Pharmaxis Investor Conference Call
4. Pharmaxis Aridol Approved for Sale in Switzerland
5. Pharmaxis Investor Conference Call
6. Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
7. New Pharmaxis Board Appointment
8. Pharmaxis Aridol Authorised for Sale in Germany
9. Pharmaxis First Steps into China
10. Pharmaxis to Apply to Market Bronchitol in Australia
11. Pharmaxis Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... of the latest paper by its Science Editor, Dr. Elisabeth Bik, in the ... Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position ...
(Date:1/18/2017)... 18, 2017 Shareholder rights law firm Johnson ... the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... with the proposed sale of the Company to Eli ... develops small molecules for the acute treatment of migraines. ... had signed a definitive merger agreement with Eli Lilly. ...
(Date:1/18/2017)... , Jan. 18, 2017  Caris Life Sciences, ... Lustgarten Foundation, the largest private funder of pancreatic ... trial evaluating the impact of immunotherapy in the ... trial enrollment services to identify potential trial candidates ... between treating physicians and study investigators. The Lustgarten ...
(Date:1/18/2017)... , Jan. 18, 2017  Market Research Future published a half-cooked ... is expected to grow at a CAGR of 12% during the ... ... due to the abnormal cell division without any control. These abnormal ... to them. These cancer cells can spread to other parts of ...
Breaking Biology Technology:
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017  For the thousands of ... , a global leader in connected health and biometric measurement devices and ... pressure monitors. On display in A&D Medical,s special CES ... monitors represent the ongoing expansion of the company,s WellnessConnected product ... ...
(Date:12/20/2016)... LONDON , Dec. 20, 2016 ... car sharing, rental and leasing is stoking significant ... of radio frequency technology, Bluetooth low energy (BLE), ... emerge as the next wave of wireless technologies ... vehicle access system to advanced access systems opens ...
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
Breaking Biology News(10 mins):